Neuropace Valuation
| NPCE Stock | USD 10.25 0.05 0.49% |
At this time, the firm appears to be overvalued. Neuropace secures a last-minute Real Value of $7.8 per share. The latest price of the firm is $10.25. Our model forecasts the value of Neuropace from analyzing the firm fundamentals such as Return On Equity of -2.15, current valuation of 321.12 M, and Profit Margin of (0.37) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Neuropace's valuation include:
Price Book 30.9937 | Enterprise Value 321.1 M | Enterprise Value Ebitda (16.94) | Price Sales 3.9822 | Enterprise Value Revenue 4.2003 |
Overvalued
Today
Please note that Neuropace's price fluctuation is moderately volatile at this time. Calculation of the real value of Neuropace is based on 3 months time horizon. Increasing Neuropace's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Neuropace stock is determined by what a typical buyer is willing to pay for full or partial control of Neuropace. Since Neuropace is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neuropace Stock. However, Neuropace's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.25 | Real 7.8 | Target 7.8 | Hype 10.31 | Naive 10.38 |
The real value of Neuropace Stock, also known as its intrinsic value, is the underlying worth of Neuropace Company, which is reflected in its stock price. It is based on Neuropace's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Neuropace's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Neuropace helps investors to forecast how Neuropace stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neuropace more accurately as focusing exclusively on Neuropace's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Neuropace's intrinsic value based on its ongoing forecasts of Neuropace's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Neuropace's closest peers. If more than one evaluation category is relevant for Neuropace we suggest using both methods to arrive at a better estimate.
Neuropace Cash |
|
Neuropace Valuation Trend
Comparing Neuropace's enterprise value against its market capitalization is a good way to estimate the value of Neuropace uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Neuropace Total Value Analysis
Neuropace is now forecasted to have valuation of 321.12 M with market capitalization of 304.45 M, debt of 72.39 M, and cash on hands of 92.41 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Neuropace fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
321.12 M | 304.45 M | 72.39 M | 92.41 M |
Neuropace Investor Information
About 83.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.98. Neuropace had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Neuropace's historical financial statements, Neuropace is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Neuropace Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Neuropace has an asset utilization ratio of 60.77 percent. This indicates that the Company is making $0.61 for each dollar of assets. An increasing asset utilization means that Neuropace is more efficient with each dollar of assets it utilizes for everyday operations.Neuropace Ownership Allocation
Neuropace maintains a total of 29.85 Million outstanding shares. The majority of Neuropace outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Neuropace to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Neuropace. Please pay attention to any change in the institutional holdings of Neuropace as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Neuropace Profitability Analysis
The company reported the previous year's revenue of 65.42 M. Net Loss for the year was (32.96 M) with profit before overhead, payroll, taxes, and interest of 32.49 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Neuropace's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Neuropace and how it compares across the competition.
About Neuropace Valuation
The stock valuation mechanism determines Neuropace's current worth on a weekly basis. Our valuation model uses a comparative analysis of Neuropace. We calculate exposure to Neuropace's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neuropace's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 48.1 M | 37.6 M | |
| Pretax Profit Margin | (0.50) | (0.53) | |
| Operating Profit Margin | (0.42) | (0.44) | |
| Net Loss | (0.50) | (0.53) | |
| Gross Profit Margin | 0.74 | 0.58 |
Neuropace Growth Indicators
Investing in growth stocks can be very risky. If the company such as Neuropace does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 25.9 M |
Neuropace Current Valuation Indicators
Valuation refers to the process of determining the present value of Neuropace and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Neuropace we look at many different elements of the entity such as Neuropace's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Neuropace, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Neuropace's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Neuropace's worth.Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |